Monthly Update: Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis: Neuroinflammatory mechanisms in Alzheimer's disease: new opportunities for drug discovery

References

• SELKOE DJ: Physiological production of the 13-amyloid protein and the mechanism of Alzheimer's disease. Trends Neurosci. (1993) 16:430–439.
   PubMedGoogle Scholar
• TARIOT PN: Alzheimer's disease: an overview. Alzhe-imer's Dis. Assoc. Dis. (1994) 8\(Suppl. 2):S4–S11.
   Google Scholar
• FIBIGER HC: Cholinergic mechanisms in learning, memory, and dementia: a review of recent evidence. Trends Neurosci. (1991) 14:220–223.
   PubMed Web of Science ®Google Scholar
• SCHNEIDER LS: Tacrine development experience: earlyclinical trials and enrichment and parallel designs. Alzheimer's Dis. Assoc. Dis. (1994) 8\(Suppl. 2):S12–S21.
   Google Scholar
• MCGEER PL, ROGERS J, MCGEER EG: Neurohnmunemechanisms in Alzheimer's disease pathogenesis. Alzheimer's Dis. Assoc. Dis. (1994) 8:149–158.
   PubMed Web of Science ®Google Scholar
• FABRY Z, RAINE CS, HART MN: Nervous tissue as animmune compartment the dialect of the immune re-sponse in the CNS. Immunol. Today (1994) 15:218–224.
   PubMedGoogle Scholar
• PERLMUTTER LS, BARRON E, CHIU HC: Morphologicassessment between microglia and senile plaque amy-loid in Alzheimer's disease. Neurosci. Lett. (1990) 119:32–36.
   PubMedGoogle Scholar
• BONDAREFF W, HARRINGTON CR, WISCHIK CM, HAUSER DL, ROTH M: Absence of abnormal hyperphosphoryla-don of tau in intracellular tangles in Alzheimer's dis-ease. J. Neuropathol. Exp. Neurol. (1995) 54:657–663.
   PubMedGoogle Scholar
• CHECLER F: Processing of the 0-amylokl precursor pro-tein and its regulation in Alzheimer's disease. J. Neuro-chem. (1995) 65:1431–1444.
   PubMed Web of Science ®Google Scholar
• SIMMONS LD, MAY PC, TOMASELLI KT, RYDEL RE, FUSONK, BRIWRIGHT S, LIEBERBURG I, BECHER GW, BREMS DN, LI WY: Secondary structure of amyloid peptide corre-lates with neurotoxic activity in vitro. Mol. Pharmacol. (1994) 45:373–379.
   PubMed Web of Science ®Google Scholar
• KOWALL NW, MCKEE AC, YANKNER BA, BEAL MF: In vivoneurotoxicity and beta-amyloid [0(1-40)] and the 13(25-35) fragment. Neurobiol. Aging (1992) 13:537–542.
   PubMed Web of Science ®Google Scholar
• SCHENK DB, RYDEL RE, MAY P, LITTLE S, LIEBERSURG I,SINHA S: Therapeutic approaches related to amyloid-0 peptide and Alzheimer's disease. J. Med. Chem. (1995) 38:4141–4154.
   PubMed Web of Science ®Google Scholar
• SNOW A, W1LLEMER J, KISILEVSKY R: Sulfated glycosami-noglycans: a common constituent of all amyloids? Lab. Invest. (1987) 57:120–123.
   Google Scholar
• GASQUE P, FONTAINE M, MORGAN BP: Complement expression in human brain. Biosynthesis of terminal pathway components and regulators in human glial cells and cell lines. J. Immunol. (1995) 154:4726–4733.
   Google Scholar
• ROGERS J, COOPER NR, WEBSTER S, SCHULTZ J, MCGEEPL, STYREN SD, CIVIN WH, BRACHOVA L, BRADT B, WARD P, LIEBERSURG I: Complement activation by fl-amyloid in Alzheimer's disease. Proc. NatL Acad. Sci. USA (1992) 89:10016–10020.
   PubMed Web of Science ®Google Scholar
• GRIFFIN WST, SHENG JG, ROBERTS GW, MRAK RE: Inter-leukin-1 expression in different plaque types in Alzhe-hner's disease: significance in plaque evolution. J. Neuropathol. Exp. Neurol. (1995) 2:276–281.
   Google Scholar
• EIKELENBOOM P, STAM FC: Immunoglobulins and com-plement factors in senile plaques. Acta Neuropathol. (Berlin) (1982) 57:239–242.
   PubMed Web of Science ®Google Scholar
• AKIYAMA H, MCGEER FL: Brain microglia constitutively express f3-2 integrins. J. Neuroimmunol. (1990) 30:81–99.
   PubMed Web of Science ®Google Scholar
• ROZENMUELLER JM, EIKELENBOOM P, PALS ST, STAM FC: Microglial cells around amyloid plaques in Alzheimer's disease express leukocyte adhesion molecules of the LFA-1 family. Neurosci. Lett. (1989) 101:288–292.
   PubMed Web of Science ®Google Scholar
• TANAKA M, SOMOMATSU A, YOSHIDA T, HIRAI S, NISHIDA A: Detection of superoxide production by activated microglia using a sensitive and specific chemi-luminescence assay and microglia-mediated PC12h cell death. J. Neurocbem. (1994) 63:266–270.
   PubMed Web of Science ®Google Scholar
• LEE SC, DICKSON DW, LIU W, BROSNAN CF: Induction ofnitric oxide synthase activity in human astrocytes by interleukin-113 and interferon-gamma. J. Neuroimmunol. (1993) 46:19–24.
   PubMed Web of Science ®Google Scholar
• DICKSON DW, LEE SC, MATTIACE LA, YEN S-H, BROSNAN C: Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. Glia (1993) 7:75–83.
   PubMed Web of Science ®Google Scholar
• STYREN SD, CIVIN WH, RODGERS J: Molecular, cellular, and pathologic characteristics of HLA-DR inununoreac-tivity in normal elderly and Alzheimer's disease brains. Exp. Neurol. (1990) 110:93–104.
   PubMedGoogle Scholar
• TOOYAMA I, KIMURA H, AKIYAMA H, MCGEER PL: Reac-tive microglia express class I and class II major histo-compatibility antigens in Alzheimer's disease. Brain Res. (1990) 523:273–280.
   PubMed Web of Science ®Google Scholar
• ITAGAKI S, MCGEER PL, AKIYAMA H: Presence of T-cyto-toxic suppressor and leucocyte common antigen posi-tive cells in Alzheimer's disease brain tissue. Neurosci. Lett. (1989) 91:259–264.
   Google Scholar
• SHALIT F, SREDNI B, KOTT E, HUBERMAN M: T-Iympho-cyte subpopulations and activation markers correlate with severity of Alzheimer's disease. Clin. Immunol. Immunopathol. (1995) 75:246–250.
   PubMedGoogle Scholar
• EIKELENBOOM P, VACK CE, ROZENMULLER JM, STAM FC: Complement activation in amyloid plaques in Alzhe-imer's disease. Virchows Arch. (1989) 36:259–262.
   Google Scholar
• SINGH VK: Studies of neuroimmune markers in Alzhe-imer's disease. MoL Neurobiol. (1994) 9:73–81.
   PubMed Web of Science ®Google Scholar
• JIANG H, BURDICK D, GLABE CG, COTMAN CW, TENNERAJ: fl-amyloid activates complement by binding to a specific region of the collagen-like domain of the Clq chain. J. Immunol. (1994) 152:5050–5059.
   PubMed Web of Science ®Google Scholar
• AKIYAMA H, KAWAMATA T, DEDHAR S, MCGEER PL: hrununohistochemical localization of viIronectin, its receptor and beta-3 integrin in Alzheimer's brain tissue. Neuroimmunol. (1991) 32:19–28.
   PubMedGoogle Scholar
• MCGEER PL, WALKER DG, AKIYAMA H, KAWAMATA T, GUAN AL, PARKER CJ, OKADA N, MCGEER EG: Detection of the brain inhibitor of reactive lysis (CD59) in dis-eased neurons of Alzheimer brain. Brain Res. (1991) 544:315–319.
   PubMed Web of Science ®Google Scholar
• MCGEER PL, KAWAMATA T, WALKER DG: Distribution ofclusterin in Alzheimer brain. Brain Res. (1992) 579:337–341.
   PubMed Web of Science ®Google Scholar
• GRIFFIN WST, STANLEY LC, LING C, WHITE L, MACLEODV, PERROT LJ, WHITE CLI, ARAOZ C: Brain interleukin-1 and S-100 immtmoreactivity are elevated in Down syndrome and Alzheimer's disease. Proc. Natl. Acad. Sci. USA (1989) 86:7611–7615.
   PubMed Web of Science ®Google Scholar
• GITTER BD, COX LM, RYDEL RE, MAY PC: Amyloid 13 peptide potentiates cytokine secretion by interleukin-113-activated human astrocytoma cells. Proc. Natl. Acad. Sci. USA (1995) 23:10738–10741.
   Google Scholar
• HARIRI RJ, CHANG VA, BARIE PS, WANG RS, SHAREF SF,GHAJAR JB: Traumatic injury induces interleukin-6 pro-duction by human astrocytes. Brain Res. (1994) 636:139–142.
   PubMed Web of Science ®Google Scholar
• CAMPBELL IL, ARBRHAM CR, MASLIAH E, KEMPER P, INGLIS J, OLDSTONE MBA, MUCKE L: Neurologic disease Induced in transgenic mice by cerebral overexpression of interleukin-6. Proc. Natl. Acad. USA (1993) 90:10061–10065.
   PubMed Web of Science ®Google Scholar
• POTTER H: The involvement of astrocytes and an acutephase response in0-amyloid deposition of Alzheimer's disease. Prog. Brain Res. (1992) 94:447–458.
   PubMed Web of Science ®Google Scholar
• RICH JB, RASMUSSON DX, FOLSTEIN MF, CARSON KA,KAWAS C, BRANDT J: Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology (1995) 45:51–55.
   PubMed Web of Science ®Google Scholar
• BEARD CM, KOKMAN E, KURLAND LT: Rheumatoid ar-thritis and susceptibility to Alzheimer's disease. lancet (1991) 337:1426.
   PubMed Web of Science ®Google Scholar
• BREITNER JCS, GAII BA, WELSH KA, PLASSMAN BL, MCDONALD WM, HELMS MJ, ANTHONY JC: Inverse asso-ciation of anti-inflammatory treatments and Alzhe-imer's disease: initial results of a co-twin control study. Neurology (194) 44:227–232.
   Google Scholar
• ROGERS J, KIRKBY LC, HEMPELMAN SR, BERRY DL, MCGEER PL, KAZNIAK AW, ZALINSKI J, COFIELD M, MAN-SUKHANI L, WILSON P, KOGAN F: Clinical trial of in-domethacin in Alzheimer's disease. Neurology (1993) 43:1609–1611.
   PubMed Web of Science ®Google Scholar
• ANONYMOUS: Pbarmaprojects. PJB Publications Ltd., Rich-mond, Surrey, UK (May 1995).
   Google Scholar
• ANONYMOUS: Drug and Market Development (28 July 1995) 6:132-134. Southborough, MA.
   Google Scholar
• WALKER DG, KIM SU, MCGEER PL: Complement and cytokine gene expression in cultured microglia derived from post-mortem human brains. J. Neurosci. Res. (1995) 40:478–493.
   PubMed Web of Science ®Google Scholar
• PODLISNY MB, STEPHENSON DT, FROSCH MP, LIEBER-BURG I, CLEMENS JA, SELKOE DJ: Synthetic amyloid-13 fails to produce specific neurotoxicity in monkey cere-bral cortex. Neurobiol. Aging (1992) 13:561–567.
   PubMed Web of Science ®Google Scholar
• BLUSZTAPN .11c: Alzheimer's disease: prevention, mod-els, and diagnostic tools. Neurobiol. Aging (1994) 15\(Suppl. 2):S37–S39.
   Google Scholar